



**P.17019/01/2021-PvPI**  
**Indian Pharmacopoeia Commission**  
**National Coordination Centre-Pharmacovigilance Programme of India**  
**(Ministry of Health & Family Welfare, Govt. of India)**

Email: [pvpi.ipc@gov.in](mailto:pvpi.ipc@gov.in), [lab.ipc@gov.in](mailto:lab.ipc@gov.in), Website: [www.ipc@gov.in](http://www.ipc@gov.in), Tel. No. 0120-2783400

Sector-23, Raj Nagar,  
Ghaziabad-201002, U.P.  
Dated: 4<sup>th</sup> January, 2021.

### Monthly Drug Safety Alert

The preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drugs are associated with the ADRs as given below.

**Table**

Sl. No	Suspected Drugs	Indication	Adverse Drug Reactions
1	Fexofenadine	In the treatment of relief of symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria.	Blurred Vision
2	Ambroxol	Anti-tussive - Acute and chronic disease of the respiratory tract associated with abnormal bronchial secretions in particular acute attacks of chronic bronchitis, asthmatic bronchitis and bronchial asthma.	Fixed Drug Eruption

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADRs associated with the use of above suspected drugs. If such reactions are encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “**ADR PvPI App**” and **PvPI Helpline No. 1800-180-3024.**